ResMed Inc (RMD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ResMed Inc (RMD) has a cash flow conversion efficiency ratio of 0.085x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($554.13 Million) by net assets ($6.49 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check RMD capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
ResMed Inc - Cash Flow Conversion Efficiency Trend (1993–2025)
This chart illustrates how ResMed Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. See RMD total equity for net asset value and shareholders' equity analysis.
ResMed Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ResMed Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GE HealthCare Technologies Inc.
NASDAQ:GEHC
|
0.027x |
|
Fortis Inc
TO:FTS
|
0.042x |
|
Sandoz Group AG
SW:SDZ
|
0.114x |
|
Tata Steel Limited
NSE:TATASTEEL
|
0.136x |
|
Hannover Rück SE
F:HNR1
|
0.128x |
|
Celltrion Inc
KO:068270
|
0.008x |
|
Dover Corporation
NYSE:DOV
|
0.026x |
|
Raymond James Financial Inc.
NYSE:RJF
|
0.011x |
Annual Cash Flow Conversion Efficiency for ResMed Inc (1993–2025)
The table below shows the annual cash flow conversion efficiency of ResMed Inc from 1993 to 2025. For the full company profile with market capitalisation and key ratios, see market value of ResMed Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $5.97 Billion | $1.75 Billion | 0.294x | +1.88% |
| 2024-06-30 | $4.86 Billion | $1.40 Billion | 0.288x | +71.61% |
| 2023-06-30 | $4.13 Billion | $693.30 Million | 0.168x | +60.67% |
| 2022-06-30 | $3.36 Billion | $351.15 Million | 0.104x | -59.07% |
| 2021-06-30 | $2.89 Billion | $736.72 Million | 0.255x | -20.54% |
| 2020-06-30 | $2.50 Billion | $802.25 Million | 0.321x | +45.03% |
| 2019-06-30 | $2.07 Billion | $459.05 Million | 0.222x | -9.68% |
| 2018-06-30 | $2.06 Billion | $505.03 Million | 0.245x | +16.12% |
| 2017-06-30 | $1.96 Billion | $414.05 Million | 0.211x | -34.67% |
| 2016-06-30 | $1.69 Billion | $547.93 Million | 0.323x | +33.92% |
| 2015-06-30 | $1.59 Billion | $383.18 Million | 0.241x | +8.48% |
| 2014-06-30 | $1.76 Billion | $391.27 Million | 0.223x | -11.03% |
| 2013-06-30 | $1.61 Billion | $402.82 Million | 0.250x | +4.94% |
| 2012-06-30 | $1.61 Billion | $383.16 Million | 0.238x | +45.66% |
| 2011-06-30 | $1.73 Billion | $283.19 Million | 0.164x | +11.93% |
| 2010-06-30 | $1.29 Billion | $188.21 Million | 0.146x | -31.76% |
| 2009-06-30 | $1.12 Billion | $238.88 Million | 0.214x | +68.11% |
| 2008-06-30 | $1.08 Billion | $137.84 Million | 0.127x | +30.24% |
| 2007-06-30 | $931.22 Million | $91.11 Million | 0.098x | -27.07% |
| 2006-06-30 | $738.15 Million | $99.03 Million | 0.134x | -10.52% |
| 2005-06-30 | $474.06 Million | $71.08 Million | 0.150x | -29.19% |
| 2004-06-30 | $361.50 Million | $76.54 Million | 0.212x | +2.30% |
| 2003-06-30 | $286.43 Million | $59.28 Million | 0.207x | +12.04% |
| 2002-06-30 | $192.93 Million | $35.64 Million | 0.185x | -37.19% |
| 2001-06-30 | $100.37 Million | $29.52 Million | 0.294x | +36.32% |
| 2000-06-30 | $93.97 Million | $20.27 Million | 0.216x | -15.11% |
| 1999-06-30 | $71.61 Million | $18.20 Million | 0.254x | +89.87% |
| 1998-06-30 | $50.80 Million | $6.80 Million | 0.134x | -37.16% |
| 1997-06-30 | $44.60 Million | $9.50 Million | 0.213x | +137.35% |
| 1996-06-30 | $39.00 Million | $3.50 Million | 0.090x | +270.51% |
| 1995-06-30 | $28.90 Million | $700.00K | 0.024x | -91.52% |
| 1994-06-30 | $5.60 Million | $1.60 Million | 0.286x | -17.14% |
| 1993-06-30 | $2.90 Million | $1.00 Million | 0.345x | -- |
About ResMed Inc
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, h… Read more